Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Miyazaki

Showing results (101-110 of 103) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 103 results.
Transplantation and Cellular Therapy|October 2, 2020
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter AnalysisTakayoshi Tachibana, Junya Kanda, Takuma Ishizaki, et al.
Transplantation and Cellular Therapy|May 21, 2026
Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agentsHiroaki Shimizu, Yuho Najima, Shinichi Kako, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
Pageof 11

Showing results (101-110 of 103) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 103 results.
Transplantation and Cellular Therapy|October 2, 2020
Clinical Benefits of Preconditioning Intervention in Patients with Relapsed or Refractory Acute Myelogenous Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A Kanto Study of Group for Cell Therapy Multicenter AnalysisTakayoshi Tachibana, Junya Kanda, Takuma Ishizaki, et al.
Transplantation and Cellular Therapy|May 21, 2026
Treatment outcomes of adult B-cell ALL with post-transplant relapse in the era of immunotherapeutic agentsHiroaki Shimizu, Yuho Najima, Shinichi Kako, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
Pageof 11